{"id":132280,"date":"2020-12-12T21:08:27","date_gmt":"2020-12-12T18:08:27","guid":{"rendered":"https:\/\/en.buradabiliyorum.com\/astrazeneca-buying-drug-developer-alexion-for-39-billion\/"},"modified":"2020-12-12T21:08:27","modified_gmt":"2020-12-12T18:08:27","slug":"astrazeneca-buying-drug-developer-alexion-for-39-billion","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/astrazeneca-buying-drug-developer-alexion-for-39-billion\/","title":{"rendered":"#AstraZeneca buying drug developer Alexion for $39 billion"},"content":{"rendered":"

“#AstraZeneca buying drug developer Alexion for $39 billion<\/strong>”<\/p>\n

\n
\n
\n
\"AstraZeneca
\n In this Jan. 29, 2009 file photo, reflections are seen on a sign outside the global headquarters of AstraZeneca in London. Cambridge, England-based pharmaceutical company AstraZeneca, which is involved in development of a COVID-19 vaccine, said Saturday Dec, 12, 2020, it is acquiring Boston-based drug developer Alexion Pharmaceuticals Inc. in a deal worth dollars 39 billion. (AP Photo\/Kirsty Wigglesworth, File)
\n <\/figcaption><\/figure>\n<\/div>\n<\/div>\n

Pharmaceutical company AstraZeneca says it is buying U.S. drug developer Alexion in a deal worth $39 billion.<\/p>\n

Cambridge, England-based AstraZeneca PLC, which is involved in one of the efforts to develop a COVID-19 vaccine, said Saturday it’s using a combination of cash and shares for the acquisition of Boston-based Alexion Pharmaceuticals Inc.<\/p>\n

The boards of both companies unanimously app<\/a>roved the transaction, which still needs regulatory and shareholder approval. The deal is expected to close in the third quarter of 2021.<\/p>\n

“This acquisition allows us to enhance our presence in immunology,” AstraZeneca CEO Pascal Soriot said in a statement.<\/p>\n

AstraZeneca and Oxford University have jointly developed a coronavirus vaccine that British and Canadian regulators are assessing, alongside a rival effort by U.S. drugmaker Pfizer and Germany’s BioNTech that has already earned some emergency approvals, and another by U.S. biotechnology<\/a> company Moderna.<\/p>\n

\n
\n
\"AstraZeneca
\n In this file photo dated Wednesday, July 24, 2013, workers walk out from AstraZeneca building in Shanghai, China. The Cambridge, England-based pharmaceutical company AstraZeneca, which is involved in development of a potential COVID-19 vaccine, said Saturday Dec, 12, 2020, it is acquiring Boston-based drug developer Alexion Pharmaceuticals Inc. in a deal worth dollars 39 billion. (AP Photo\/Eugene Hoshiko)
\n <\/figcaption><\/figure>\n<\/div>\n<\/div>\n\n
\n

Follow the latest news<\/a> on the coronavirus (COVID-19) outbreak\n <\/p><\/div>\n

\n

\n \u00a9 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.\n <\/p>\n

<\/p>\n

\n

Citation<\/strong>:
\n AstraZeneca buying drug developer Alexion for $39 billion (2020, December 12)
\n retrieved 12 December 2020
\n from https:\/\/medicalxpress.com\/news\/2020-12-astrazeneca-drug-alexion-billion.html<\/p>\n

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
\n part may be reproduced without the written permission. The content is provided for information purposes only.<\/p><\/div>\n<\/p><\/div>\n